The effect of PYY (3-36) on bone turnover markers in obese patient with type 2 diabetes
File(s)P1_Alexiadou.pdf (23.67 MB)
Published version
Author(s)
Type
Conference Paper
Abstract
Background: Gut hormones have emerged as new promising therapies for the treatment of obesity and type 2 diabetes as well as viable alternatives to bariatric surgery. PYY has mainly been studied for its effect on appetite suppression and lately for its role in diabetes remission post-bariatric surgery. Animal data have suggested that PYY may act on the bone remodelling process by increasing bone resorption.
Aims: The aim of our study was to assess the effect of PYY infusion on bone turn over markers in obese patients with type 2 diabetes.
Methods: Ten obese patients with type 2 diabetes on diet or one hypoglycaemic agent were enrolled in the study. An infusion of PYY (3-36) was administered daily for up to 16 hours for a duration of 4 weeks. Metabolic profiling at fasting state and during a Mixed Meal Test (MMT) was performed prior to the initiation of the infusion and at the end of 4 weeks. Bone markers (plasma P1NP, CTX, OC) were measured at the beginning and the end of the 4 weeks both at fasting state and during the MMT. Urinary NTX was measured at fasting state only.
Results: There was no significant difference in bone markers before and after the intervention. P1NP and CTX reduced significantly during the MMT compared to the fasting state both prior and 4 weeks after the infusion of PYY (3-36).
Conclusions: Infusion of PYY (3-36) for 4 weeks does not affect the bone turnover markers in obese patients with type 2 diabetes. P1NP and CTX reduce significantly as a response to nutrient intake. PYY (3-36) could be developed as treatment for obesity with type 2 diabetes without negative implications for bone health.
Aims: The aim of our study was to assess the effect of PYY infusion on bone turn over markers in obese patients with type 2 diabetes.
Methods: Ten obese patients with type 2 diabetes on diet or one hypoglycaemic agent were enrolled in the study. An infusion of PYY (3-36) was administered daily for up to 16 hours for a duration of 4 weeks. Metabolic profiling at fasting state and during a Mixed Meal Test (MMT) was performed prior to the initiation of the infusion and at the end of 4 weeks. Bone markers (plasma P1NP, CTX, OC) were measured at the beginning and the end of the 4 weeks both at fasting state and during the MMT. Urinary NTX was measured at fasting state only.
Results: There was no significant difference in bone markers before and after the intervention. P1NP and CTX reduced significantly during the MMT compared to the fasting state both prior and 4 weeks after the infusion of PYY (3-36).
Conclusions: Infusion of PYY (3-36) for 4 weeks does not affect the bone turnover markers in obese patients with type 2 diabetes. P1NP and CTX reduce significantly as a response to nutrient intake. PYY (3-36) could be developed as treatment for obesity with type 2 diabetes without negative implications for bone health.
Date Issued
2022-03-01
Date Acceptance
2022-03-01
Citation
Diabetic Medicine, 2022, 39, pp.1-1
ISSN
0742-3071
Publisher
Wiley
Start Page
1
End Page
1
Journal / Book Title
Diabetic Medicine
Volume
39
Copyright Statement
© 2022 The Authors, presented at the Diabetes UK Professional Conference © 2022 Diabetes UK. This is the accepted version of the following article: (2022), Poster abstracts. Diabet. Med., 39: e14810, which has been published in final form at https://doi.org/10.1111/dme.14810
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000773509700063&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Source
Diabetes UK Professional Conference 2022
Subjects
Science & Technology
Life Sciences & Biomedicine
Endocrinology & Metabolism
Publication Status
Published
Start Date
2022-03-29
Coverage Spatial
London, Online event
Date Publish Online
2022-03-28